Skip to main content
. 2024 Feb 8;20(1):2309693. doi: 10.1080/21645515.2024.2309693

Figure 1.

Figure 1.

Development and testing of human ESR1 targeting vaccines. (a) Diagram of E1 region for [E1-,E3-] adenoviral ESR1 vaccines. (b,c) C57BL/6J mice (b) and HLA-A2-Tg (c) were vaccinated with indicated viruses and assessed for ESR1-specific T cell responses at 2 weeks post vaccination through IFNγ ELISPOT (n = 5 mice/group). (d) HLA-A2 tg mice were vaccinated with the indicated viruses and assessed for ESR1-specific T cell responses at 2 weeks post vaccination through IFNγ ELISPOT (n = 3–4 mice/group). Error bars represent SEM. Select p values shown. Significance determined via T test with Bonferroni correction for multiple comparisons. ****p < .0001.